How much clinical evidence exists for medical cannabis?

There are now over 100 published clinical trials examining cannabis-based medicines across conditions including chronic pain, epilepsy, multiple sclerosis spasticity, PTSD, and cancer-related symptoms. Real-world evidence programmes — most notably Project Twenty21 in the UK and the large German observational dataset — have added tens of thousands of patient-years of outcome data.

What is the endocannabinoid system?

The endocannabinoid system (ECS) is a regulatory network present throughout the human body comprising cannabinoid receptors (CB1 and CB2), endogenous ligands (anandamide and 2-arachidonoylglycerol, known as 2-AG), and the enzymes that synthesise and break them down. The ECS modulates pain perception, immune function, mood, memory, appetite, and sleep. Cannabinoids in medical cannabis work by interacting with this system — THC primarily activates CB1 receptors in the brain and nervous system, while CBD modulates the system indirectly and has a broader target profile.

What did Project Twenty21 find?

Project Twenty21 was a UK real-world evidence programme run by Drug Science that enrolled over 3,000 patients between 2019 and 2022. Patients reported significant improvements in pain scores, anxiety, sleep quality, and overall quality of life after starting medical cannabis treatment, with a favourable tolerability profile. The programme provided the largest dataset of UK patient outcomes and formed the basis for several peer-reviewed publications.

How does UK medical cannabis evidence compare to Germany?

Germany has amassed significantly more real-world outcome data due to its larger patient population and earlier rescheduling (2017 versus 2018 in the UK). German observational data from over 100,000 patients shows consistent efficacy across pain, neurology, and psychiatric indications with a well-characterised safety profile. UK data from programmes like Project Twenty21 mirrors German findings — confirming that European patients respond similarly and validating the use of EU-GMP products across both markets.

Is medical cannabis research ongoing?

Yes. Active research includes Phase II and III randomised controlled trials in the UK, EU, and USA examining cannabinoids for neuropathic pain, PTSD, treatment-resistant depression, Parkinson's disease, and inflammatory bowel disease. The field is moving rapidly from observational evidence to higher-quality interventional trial data.

Science & Evidence

Medical Cannabis Research & Evidence

The clinical evidence base for cannabis-based medicines has grown substantially over the past decade. Here we summarise the key research, explain the science, and put UK data in its European context.

View Our Strains Contact Medical Team

Doctor reviewing medical cannabis patient records compliance UK clinic

100+ Clinical Studies

10+ Years of Data

120k+ Patients in Studies

30+ Conditions Studied

Key Research Areas

Where the Evidence Is Strongest

🧈

Pain Research

Cannabinoids reduce neuropathic pain scores by 30–50% in multiple RCTs
THC-dominant products show particular efficacy in central sensitisation pain states

🧠

Neurology

CBD-based Epidyolex is a licensed medicine for Dravet syndrome and Lennox-Gastaut — a landmark in cannabis regulation
MS spasticity evidence: Sativex (nabiximols) is licensed in the UK, validating the cannabinoid mechanism

🏗

Oncology

Chemotherapy-induced nausea and vomiting — cannabinoids recommended in NICE guidelines as second-line antiemetics
Cancer pain management: observational data shows significant opioid-sparing effects in real-world oncology settings

🕑

Mental Health

PTSD is the most evidence-rich psychiatric indication — RCT data supports THC for nightmare suppression and hyperarousal
CBD shows significant anxiolytic effects in clinical studies with doses of 300–600 mg for acute anxiety

💤

Sleep

Project Twenty21 data: sleep was the most-improved patient-reported outcome among cannabis users
Low-dose THC promotes sleep onset; CBD at higher doses improves sleep architecture without sedation hangover

🔥

Inflammation

Both CB1 and CB2 receptors modulate inflammatory cytokine release — a mechanism relevant to IBD, RA, and autoimmune conditions
Preclinical data on CBD as an anti-inflammatory agent is robust; clinical translation studies are now progressing

The Science

The Endocannabinoid System Explained

The human body produces its own cannabis-like compounds. The endocannabinoid system (ECS) is the regulatory network that uses these molecules — and it is the reason medical cannabis can have such wide-ranging effects.

CB1 Receptors

Found primarily in the brain and central nervous system. CB1 activation by THC is responsible for psychoactive effects but also pain modulation, appetite regulation, and neuroprotection. CB1 receptors are highly concentrated in areas governing pain perception, mood, and memory.

CB2 Receptors

Concentrated in immune tissue, the gut, and peripheral nervous system. CB2 activation plays a central role in immune modulation and anti-inflammatory signalling — which is why medical cannabis is relevant to conditions like Crohn's disease, rheumatoid arthritis, and inflammatory pain states.

Anandamide & 2-AG

These are the body's own cannabinoids — endogenous ligands that activate CB1 and CB2 receptors. Anandamide (from the Sanskrit word for bliss) is linked to mood and pain tolerance. 2-arachidonoylglycerol (2-AG) is the most abundant endocannabinoid and plays a key role in immune regulation. Plant cannabinoids mimic and modulate these natural signals.

CBD does not bind directly to CB1 or CB2 receptors in the same way as THC. Instead it modulates the ECS indirectly — inhibiting the enzyme that breaks down anandamide, interacting with serotonin receptors, and blocking certain ion channels involved in pain and inflammation. This broad, indirect mechanism helps explain CBD's favourable tolerability profile and wide therapeutic range.

Real World Evidence

What Real-World Data Tells Us

Project Twenty21 (UK)

Drug Science's landmark UK real-world evidence programme enrolled over 3,000 patients between 2019 and 2022. Key findings:

Statistically significant improvements in pain, anxiety, sleep, and quality of life
Sleep quality showed the greatest improvement of all measured outcomes
Low rates of serious adverse events — tolerability profile comparable to observational European data
Most common indications: chronic pain (42%), PTSD (19%), anxiety (14%)

German Observational Data

Germany legalised medical cannabis in 2017 and has accumulated the largest European real-world dataset. Headline findings from 120,000+ patients:

Pain, multiple sclerosis, ADHD, and psychiatric disorders are the most prescribed indications
Consistent efficacy across pain subtypes including neuropathic and musculoskeletal
Significant opioid-sparing effect documented in chronic pain cohorts
UK findings are closely aligned — validating the use of EU-GMP European products in British patients

Explore Our Strain Portfolio

Every Cannamedical Britannia product is EU-GMP certified and fully characterised — the same standard used in the clinical trials cited on this page.

View Our Strains Contact Our Medical Team